Marksans Pharma FY25 PAT up 21% at Rs. 382.6 Cr
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
EBITDA for the period rose by 23.2% to Rs. 3,797 million
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
She has held senior positions at Coca-Cola in China and PepsiCo in India
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
Subscribe To Our Newsletter & Stay Updated